United Therapeutics Corp
UTHR: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$457.00 | Vrk | Dytwsnly |
United Therapeutics Reports Solid Q4, Long-Term Outlook Are Unchanged; Maintaining $208 FVE
United Therapeutics reported solid fourth-quarter results highlighted by revenue of $415 million, and the company ended the year with total revenue of $1.7 billion, representing a nearly 14% increase from 2020. We maintain our fair value estimate of $208 per share, our no-moat rating, and stable moat trend.